[Clinical Breakdown] Evaluating Gut Hormone Changes (Glp-1, Pyy) Triggered By Esg Volume Changes

#Clinical #Breakdown #Evaluating #Hormone #Changes #Triggered #Volume #Changes

GLP-1 What it is and why it needs estrogen to work properly Felice Gersh, MD by Felice Gersh

Title: GLP-1 What it is and why it needs estrogen to work properly Felice Gersh, MD
Channel: Felice Gersh
[Q&A Brief] What Is The Age Limit For Bariatric Surgery? Adolescent And Senior Qualification Rules

[Clinical Breakdown] Evaluating Gut Hormone Changes (GLP-1, PYY) Triggered by ESG Volume Changes

For years, Endoscopic Sleeve Gastroplasty (ESG) was viewed strictly through a mechanical lens. Clinicians and patients alike assumed that suturing the stomach to reduce its volume simply acted as a physical barrier to overeating.

However, modern bariatric science has revealed a far more complex reality.

ESG does not just shrink the stomach; it fundamentally rewires the gut-brain axis. By altering gastric volume and motility, ESG triggers profound changes in key satiety hormones—most notably Glucagon-Like Peptide-1 (GLP-1) and Peptide YY (PYY).

This clinical breakdown evaluates how ESG-induced volume changes drive these endocrine shifts, what it means for long-term weight loss, and how these insights are reshaping metabolic medicine.

The Science of Endoscopic Sleeve Gastroplasty (ESG): Beyond Simple Restriction

Endoscopic Sleeve Gastroplasty is a minimally invasive procedure where an endoscopic suturing device (such as the Apollo Overstitch) is used to create a accordion-like sleeve, reducing total gastric volume by approximately 70% to 80%.

[Normal Stomach] ──(ESG Suturing)──> [Tubular Sleeve] (70-80% Volume Reduction)
                                             │
                                             ▼
                                  Altered Gastric Emptying
                                             │
                                             ▼
                                  Accelerated Distal Nutrient Delivery
                                             │
                                             ▼
                                  Upregulated GLP-1 & PYY Secretion

How Gastric Volume Reduction Alters Physiology

While surgical procedures like the Laparoscopic Sleeve Gastrectomy (LSG) physically remove the gastric fundus, ESG leaves the gastric anatomy intact but structurally altered. This anatomical preservation has unique physiological consequences:

Increased Intragastric Pressure: A smaller gastric reservoir means that even small volumes of food stretch the stomach wall rapidly.
Altered Accommodation: The stomach’s ability to relax and accommodate large food boluses is significantly reduced.
Vagal Nerve Stimulation: The rapid mechanical stretching of the gastric wall sends immediate signals via the vagus nerve to the solitary tract in the brainstem, signaling fullness.

The Hormonal Axis: Decoding GLP-1 and PYY

To understand how ESG drives metabolic success, we must examine the two primary enterogastrone hormones secreted by the enteroendocrine L-cells of the distal small intestine (ileum) and colon.

1. Glucagon-Like Peptide-1 (GLP-1)

GLP-1 is a multi-functional peptide hormone with several critical roles:

Satiety Induction: Acts directly on the arcuate nucleus in the hypothalamus to suppress appetite.
Incretin Effect: Stimulates glucose-dependent insulin secretion from pancreatic beta cells while suppressing glucagon.
Gastric Brake: Slows gastric emptying, keeping food in the stomach longer to prolong the sensation of fullness.

2. Peptide YY (PYY)

PYY is co-secreted with GLP-1 in response to nutrient ingestion, particularly fats and proteins:

Appetite Suppression: Binds to Y2 receptors in the brain to reduce hunger.
Ileal Brake: Inhibits proximal gastrointestinal motility and secretions, optimizing nutrient absorption and reinforcing satiety.

How ESG Volume Changes Trigger Gut Hormone Fluctuations

The physiological link between a smaller stomach volume and hormones produced in the lower intestine boils down to nutrient transit dynamics and mechanoreceptor activation.

                           ┌────────────────────────┐
                           │  ESG Volume Reduction  │
                           └───────────┬────────────┘
                                       │
                ┌──────────────────────┴──────────────────────┐
                ▼                                             ▼
  ┌───────────────────────────┐                 ┌───────────────────────────┐
  │   Mechanoreceptor Link    │                 │   Nutrient Transit Link   │
  └─────────────┬─────────────┘                 └─────────────┬─────────────┘
                │                                             │
                ▼                                             ▼
  Rapid gastric wall stretch                    Altered gastric emptying
                │                                             │
                ▼                                             ▼
  Vagal signaling to brain                      Rapid delivery of nutrients
                │                               to distal ileum L-cells
                ▼                                             │
   Synergistic Satiety Signal                                 ▼
                │                                 Upregulated release of
                └──────────────────────┬────────────────  GLP-1 and PYY
                                       │
                                       ▼
                         ┌──────────────────────────┐
                         │ Sustained Appetite Loss  │
                         └──────────────────────────┘

The Mechanoreceptor-Humoral Link

When gastric volume is reduced by 70%+, the intragastric pressure spikes quickly during a meal. This mechanical tension activates stretch-sensitive mechanoreceptors in the stomach wall.

These receptors send afferent signals to the brain, which synergizes with the circulating GLP-1 and PYY levels, amplifying the overall satiety signal.

Accelerated Distal Nutrient Delivery

Because the stomach's holding capacity is restricted, food breakdown is altered.

Chyme Transit: Partially digested food (chyme) is pushed through the pylorus and enters the duodenum and jejunum more rapidly than in an unaltered stomach.
L-Cell Stimulation: This rapid delivery of nutrient-rich chyme to the distal small intestine triggers the immediate, robust release of GLP-1 and PYY from L-cells.
The Hormonal Spike: Clinical studies show that postprandial (post-meal) levels of both GLP-1 and PYY are significantly higher in post-ESG patients compared to their pre-procedure baselines.

Comparing ESG vs. Surgical Sleeve Gastrectomy (VSG) Hormone Profiles

While both procedures aim to reduce gastric volume, their hormonal profiles differ because ESG preserves the gastric tissue, whereas VSG excises it.

Clinical Implications: Predicting Weight Loss and Metabolic Success

Understanding the endocrine shifts triggered by ESG volume changes allows clinicians to optimize patient care, manage expectations, and design highly targeted metabolic therapies.

Patient Selection and Personalized Medicine

Not all patients experience the same hormonal surge after ESG. Patients who present with baseline insulin resistance or blunted GLP-1 responses may experience a profound metabolic "reset" following the procedure.

Measuring early postprandial satiety can serve as a clinical marker for how effectively the volume change has triggered the GLP-1/PYY axis.

Combining ESG with Pharmacotherapy (The Synergy Era)

One of the most exciting frontiers in obesity medicine is combining ESG with GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide).

The Clinical Problem: Over time (typically 12–18 months post-op), the stomach sleeve can stretch slightly, and the body may adapt to the hormonal changes, leading to weight loss plateaus.
The Combined Solution: Introducing a low-dose GLP-1 receptor agonist targets the same receptor pathways upregulated by the ESG volume change.
The Result: A synergistic effect that tackles obesity from both a structural (mechanical) and pharmacological (chemical) angle, helping patients break through plateaus and maintain long-term weight loss.

Key Takeaways for Clinicians and Patients

ESG is Metabolic, Not Just Restrictive: The primary driver of weight loss in ESG is not merely "not being able to eat," but rather the early and sustained release of satiety hormones (GLP-1 and PYY) caused by altered gastric volume.
Anatomy Preservation Matters: Because ESG does not remove the stomach tissue, ghrelin levels may not drop as drastically as they do in surgical sleeves. However, the elevation of GLP-1 and PYY effectively counterbalances this.
Strategic Combination Therapies: The future of metabolic health lies in combination therapy. Leveraging the structural volume changes of an ESG alongside modern anti-obesity medications offers a highly effective, dual-action approach to long-term weight management.

[Policy Alert] Health Agencies Urge Increased Monitoring For Depression And Mood Changes